# A Study of of HOT1030 in Patients With Advanced Solid Tumors

> **NCT05060263** · PHASE1 · UNKNOWN · sponsor: **Huabo Biopharm Co., Ltd.** · enrollment: 42 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** HOT-1030

## Key facts

- **NCT ID:** NCT05060263
- **Lead sponsor:** Huabo Biopharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-12
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05060263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05060263, "A Study of of HOT1030 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05060263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*